
|Videos|July 1, 2015
Palbociclib Combined With Fulvestrant in Relapsed Metastatic HR+/HER2- Breast Cancer
Author(s)Shannon Puhalla, MD
Shannon Puhalla, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses a phase III study examining the combination of palbociclib and fulvestrant for the treatment of patients with relapsed metastatic hormone receptor-positive, HER2-negative breast cancer.



















